Navigation Links
Animal study suggests that newborn period may be crucial time to prevent later diabetes
Date:11/2/2011

Pediatric researchers who tested newborn animals with an existing human drug used in adults with diabetes report that this drug, when given very early in life, prevents diabetes from developing in adult animals. If this finding can be repeated in humans, it may become a way to prevent at-risk infants from developing type 2 diabetes.

"We uncovered a novel mechanism to prevent the later development of diabetes in this animal study," said senior author Rebecca A. Simmons, M.D., a neonatologist at The Children's Hospital of Philadelphia. "This may indicate that there is an important developmental window, a period of time in which we can intervene to permanently protect the body's insulin-producing cells."

Simmons and lead author Sara E. Pinney, M.D., a pediatric endocrinologist at Children's Hospital, published the study in the October issue of Diabetologia.

The research may be relevant to children with intrauterine growth retardation (IUGR), a common complication during the mother's pregnancy. Simmons' previous research showed that IUGR, which is associated with decreased availability of nutrients and hormones to the developing fetus, permanently alters gene expression and impairs the function of insulin-producing cells in the pancreas. These defects have been shown to cause type 2 diabetes to develop in adulthood.

The study team used exendin-4 (Ex-4), a drug recently approved for use in adults with type 2 diabetesa condition in which a patient produces insufficient insulin, or is unable to process insulin normally. Although the drug's mechanism is not known, it has a hormone-like effect, raising insulin secretion in adults.

In their study, Simmons and Pinney used rats with an induced form of IUGR. They found that after being given to newborn rats, Ex-4 had epigenetic effectsmodifying gene function without changing the underlying DNA sequences. Ex-4 increased the expression of a gene called Pdx1 that is necessary for beta cells to function properly. Beta cells produce insulin in the pancreas of mammals, including humans.

"In our study, giving exendin-4 during the newborn period had permanent beneficial effects on beta cells," said Pinney. "This could be important for people, in whom abnormal changes in infancy may irreversibly alter beta cells and lead to adult-onset diabetes. If we can establish that treating at-risk human babies with exendin-4 or a similar compound has corresponding effects, we may have a new preventive approach for type 2 diabetes."

Simmons and Pinney cautioned that much follow-up research remains to be done, such as investigating more of the basic biology and evaluating the genome-wide effects of exendin-4, before their research findings could translate into clinical use in children.


'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. Researchers find animal with ability to survive climate change
3. Researchers note differences between people and animals on calorie restriction
4. Earliest animal footprints ever found -- discovered in Nevada
5. Details of evolutionary transition from fish to land animals revealed
6. Drug-embedded microparticles bolster heart function in animal studies
7. Swamping bad cells with good in ALS animal models helps sustain breathing
8. Moderate use averts failure of type 2 diabetes drugs in animal model
9. Grapes may aid a bunch of heart risk factors, animal study finds
10. Animal and biological science highlights: San Antonio Fluid Dynamics Conference, Nov. 23-25
11. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... be demonstrating its new Bioflash MailGuardtm mail security screening solution at the National ... The Bioflash MailGuard system provides a fast, highly accurate, easy to use and ...
(Date:4/25/2017)... ... , ... As part of the Stago EdVantage Virtual University Virtual ... in order to illuminate this clinical problem for people unfamiliar with the topic. , ... a high degree of morbidity and mortality. DIC is a confusing disorder from both ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, ... on May 15, 2017. , Dr. Terzella completed his residency in Physical Medicine ...
(Date:4/24/2017)... 24, 2017  Dante Labs announced today the offer of ... (ca. $900). While American individuals have been able to access ... can access WGS below EUR 1,000. The sequencing ... genetic information to make informed decisions about disease monitoring, prevention, ... ...
Breaking Biology Technology: